Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
Merck
Baxter
Moodys
Johnson and Johnson

Last Updated: October 15, 2019

DrugPatentWatch Database Preview

BRIDION Drug Profile

See Plans and Pricing

« Back to Dashboard

Which patents cover Bridion, and when can generic versions of Bridion launch?

Bridion is a drug marketed by Organon Sub Merck and is included in one NDA. There are three patents protecting this drug.

This drug has fifty-five patent family members in thirty countries.

The generic ingredient in BRIDION is sugammadex sodium. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the sugammadex sodium profile page.

Drug patent expirations by year for BRIDION
Drug Prices for BRIDION

See drug prices for BRIDION

Generic Entry Opportunity Date for BRIDION
Generic Entry Date for BRIDION*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for BRIDION

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of South FloridaPhase 3
Yonsei UniversityN/A
McGill University Health CenterN/A

See all BRIDION clinical trials

Pharmacology for BRIDION
Synonyms for BRIDION
1202253-72-2
343306-71-8
343306-79-6
361LPM2T56
862667-16-1
AC-30384
Bridion (TN)
CHEBI:90952
CHEBI:90953
D05940
DB06206
ERJ6X2MXV7
EX-A2600
gamma-Cyclodextrin, 6A,6B,6C,6D,6E,7F,6G,6H-octakis-S-(2-carboxyethyl)-6A,6B,6C,6D,6E,7F,6G,6H-octathio-, octasodium salt
MK-8616
Octasodium 6,6',6'',6''',6'''',6''''',6'''''',6'''''''-octakis-S-(2-carboxylatoethyl)-6,6',6'',6''',6'''',6''''',6'''''',6'''''''-octathiocyclo-alpha-(1-4)-D-octaglucopyranoside
Org 25969
ORG-25969
SCH-900616
SCHEMBL13917069
Sugammadex
Sugammadex [USAN:INN:BAN]
Sugammadex Sodium
Sugammadex sodium (JAN/USAN)
Sugammadex sodium [USAN:JAN]
UNII-361LPM2T56
UNII-ERJ6X2MXV7

US Patents and Regulatory Information for BRIDION

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Organon Sub Merck BRIDION sugammadex sodium SOLUTION;INTRAVENOUS 022225-002 Dec 15, 2015 RX Yes No   See Pricing   See Pricing Y Y   See Pricing
Organon Sub Merck BRIDION sugammadex sodium SOLUTION;INTRAVENOUS 022225-001 Dec 15, 2015 RX Yes Yes   See Pricing   See Pricing Y Y   See Pricing
Organon Sub Merck BRIDION sugammadex sodium SOLUTION;INTRAVENOUS 022225-002 Dec 15, 2015 RX Yes No   See Pricing   See Pricing   See Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for BRIDION

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1259550 300356 Netherlands   See Pricing
1259550 47/2008 Austria   See Pricing PRODUCT NAME: SUGAMMADEX; 6-PER-DEOXY-6-PER-(2-CARBOXYETHYL) THIO-Y-CYCLODEXTRIN UND PHARMAZEUTISCH VERTRAEGLICHES SALZ HIERVON; REGISTRATION NO/DATE: EU/1/08/466/001-002 20080725
1259550 SPC031/2008 Ireland   See Pricing SPC031/2008: 20090428, EXPIRES: 20230724
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
Mallinckrodt
Express Scripts
Baxter
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.